15 Jul 2024
// PRESS RELEASE
24 Jun 2024
// PRESS RELEASE
10 May 2024
// PRESS RELEASE
KEY SERVICESAbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
About
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Booth #5.1C82
28-30 October, 2025
Industry Trade Show
Attending
03-06 November, 2025
Industry Trade Show
Attending
03-05 November, 2025
CONTACT DETAILS




Events
Webinars & Exhibitions
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Booth #5.1C82
28-30 October, 2025
Industry Trade Show
Attending
03-06 November, 2025
Industry Trade Show
Attending
03-05 November, 2025
CORPORATE CONTENT #SupplierSpotlight
https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-novo-s-parent-buys-catalent-for-us-16-5-bn-fujifilm-merck-kgaa-axplora-lonza-expand-capabilities
https://www.pharmacompass.com/radio-compass-blog/ophthalmic-dealmakers-novartis-abbvie-forge-deals-to-develop-ocular-gene-therapies

15 Jul 2024
// PRESS RELEASE
https://www.abbviecontractmfg.com/news-and-insights/success-factors-for-pre-filled-syringe-cmo-selection.html

24 Jun 2024
// PRESS RELEASE
https://www.abbviecontractmfg.com/news-and-insights/how-abbvie-operations-and-contract-manufacturing-has-prepared-global-parenteral-sites-for-the-annex-1-compliance-requirement.html

10 May 2024
// PRESS RELEASE
https://www.abbviecontractmfg.com/news-and-insights/translating-environmental-social-and-governance-esg-benefits-to-our-partners.html

20 Mar 2024
// PRESS RELEASE
https://www.abbviecontractmfg.com/news-and-insights/AbbVie-Contract-Manufacturing-12-Time-CMO-Leadership-Award-Winner.html#:~:text=AbbVie%20Contract%20Manufacturing%20%E2%80%93%2012%2DTime%20CMO%20Leadership%20Award%20Winner&text=AbbVie%20Contract%20Manufacturing%20has%20been,industry%20research%20and%20customer%20surveys.

11 Mar 2024
// PRESS RELEASE
https://www.abbviecontractmfg.com/news-and-insights/abbvie-contract-manufacturing-recognized-by-life-science-leader-for-the-11th-year.html

18 Jan 2024
// PRESS RELEASE
https://www.abbviecontractmfg.com/news-and-insights/Four-Myths-About-Embedded-CMOs-Busted.html
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13800
Submission : 1998-09-01
Status : Active
Type : II
Certificate Number : R1-CEP 1998-093 - Rev 07
Issue Date : 2020-10-09
Type : Chemical and TSE
Substance Number : 994
Status : Valid
NDC Package Code : 0074-5503
Start Marketing Date : 2010-05-24
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : AbbVie Korea Co., Ltd.
Registration Date : 2005-08-31
Registration Number : 20050831-18-C-100-05
Manufacturer Name : AbbVie Inc.
Manufacturer Address : 1401 Sheridan Road, North Chicago, IL, 60064-4000, USA
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13197
Submission : 1998-04-30
Status : Active
Type : II
Certificate Number : R1-CEP 2016-267 - Rev 00
Issue Date : 2022-03-14
Type : Chemical
Substance Number : 179
Status : Valid
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-05-09
Pay. Date : 2013-09-25
DMF Number : 27155
Submission : 2015-11-10
Status : Active
Type : II
Certificate Number : R1-CEP 1997-001 - Rev 08
Issue Date : 2023-05-23
Type : Chemical
Substance Number : 179
Status : Valid
Certificate Number : R2-CEP 1995-038 - Rev 05
Issue Date : 2019-01-24
Type : Chemical
Substance Number : 1074
Status : Valid
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8904
Submission : 1990-12-20
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13443
Submission : 1998-09-01
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13372
Submission : 1998-09-01
Status : Active
Type : II
Certificate Number : R1-CEP 2006-292 - Rev 00
Issue Date : 2012-09-24
Type : Chemical
Substance Number : 1673
Status : Valid
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24315
Submission : 2010-11-30
Status : Active
Type : II
NDC Package Code : 68513-1054
Start Marketing Date : 2011-09-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Certificate Number : R1-CEP 2012-397 - Rev 00
Issue Date : 2019-09-19
Type : Chemical
Substance Number : 2136
Status : Valid
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8904
Submission : 1990-12-20
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13800
Submission : 1998-09-01
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2016-05-09
Pay. Date : 2013-09-25
DMF Number : 27155
Submission : 2015-11-10
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13197
Submission : 1998-04-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13443
Submission : 1998-09-01
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13372
Submission : 1998-09-01
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24315
Submission : 2010-11-30
Status : Active
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Certificate Numbers : R2-CEP 1995-038 - Rev 05
Status : Valid
Issue Date : 2019-01-24
Type : Chemical
Substance Number : 1074
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Certificate Numbers : R1-CEP 1998-093 - Rev 07
Status : Valid
Issue Date : 2020-10-09
Type : Chemical and TSE
Substance Number : 994
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Certificate Numbers : R1-CEP 1997-001 - Rev 08
Status : Valid
Issue Date : 2023-05-23
Type : Chemical
Substance Number : 179
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Certificate Numbers : R1-CEP 2016-267 - Rev 00
Status : Valid
Issue Date : 2022-03-14
Type : Chemical
Substance Number : 179
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Certificate Numbers : R1-CEP 2006-292 - Rev 00
Status : Valid
Issue Date : 2012-09-24
Type : Chemical
Substance Number : 1673
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Certificate Numbers : R1-CEP 2012-397 - Rev 00
Status : Valid
Issue Date : 2019-09-19
Type : Chemical
Substance Number : 2136
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Emraclidine is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Schizophrenia.
Lead Product(s): Emraclidine,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 28, 2025
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Emraclidine,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Emraclidine Safety, Disease Activity, PK In Adults with Schizophrenia
Details : Emraclidine is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Schizophrenia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 28, 2025
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
ABBV-8736 is a Antibody drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.
Lead Product(s): ABBV-8736,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 26, 2025
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ABBV-8736,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ABBV-8736 IV Infusion Safety, Tolerability & PK In Healthy Adults
Details : ABBV-8736 is a Antibody drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 26, 2025
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
AbbVie will GM-2505 (bretisilocin) acquire Gilgamesh's lead investigational candidate, currently in development for the treatment of patients with moderate-to-severe major depressive disorder.
Lead Product(s): Bretisilocin,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: GM-2505
Study Phase: Phase IIProduct Type: Miscellaneous
Recipient: Gilgamesh Pharmaceuticals
Deal Size: $1,200.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition August 25, 2025
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Bretisilocin,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Recipient : Gilgamesh Pharmaceuticals
Deal Size : $1,200.0 million
Deal Type : Acquisition
AbbVie to Acquire Gilgamesh Bretisilocin, a Novel, Investigational Therapy
Details : AbbVie will GM-2505 (bretisilocin) acquire Gilgamesh's lead investigational candidate, currently in development for the treatment of patients with moderate-to-severe major depressive disorder.
Product Name : GM-2505
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 25, 2025
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
ABBV-277 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.
Lead Product(s): ABBV-277,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 22, 2025
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ABBV-277,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, PK, and Immunogenicity of ABBV-277 In Healthy Adults
Details : ABBV-277 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 22, 2025
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Through the acqusition, Abbvie will leverage Capstan pipeline, including CPTX2309, anti-CD19 CAR-T therapy candidate, currently in Phase 1, in development for the treatment of autoimmune diseases.
Lead Product(s): CPTX2309,Inapplicable
Therapeutic Area: Immunology Brand Name: CPTX2309
Study Phase: Phase IProduct Type: Cell & Gene Therapy
Recipient: Capstan Therapeutics
Deal Size: $2,100.0 million Upfront Cash: $2,100.0 million
Deal Type: Acquisition August 19, 2025
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CPTX2309,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase I
Recipient : Capstan Therapeutics
Deal Size : $2,100.0 million
Deal Type : Acquisition
AbbVie Completes Acquisition of Capstan Therapeutics
Details : Through the acqusition, Abbvie will leverage Capstan pipeline, including CPTX2309, anti-CD19 CAR-T therapy candidate, currently in Phase 1, in development for the treatment of autoimmune diseases.
Product Name : CPTX2309
Product Type : Cell & Gene Therapy
Upfront Cash : $2,100.0 million
August 19, 2025
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Etentamig is a Antibody drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Multiple Myeloma.
Lead Product(s): Etentamig,Daratumumab,Lenalidomide,Dexamethasone
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Antibody, Unconjugated
Sponsor: IFM (Intergroupe Français du Myélome) | PETHEMA (Program for the Study and Treatment of Haematological Malignances)
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 31, 2025
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Etentamig,Daratumumab,Lenalidomide,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : IFM (Intergroupe Français du Myélome) | PETHEMA (Program for the Study and Treatment of Haematological Malignances)
Deal Size : Inapplicable
Deal Type : Inapplicable
Etentamig+Daratumumab vs DRd Safety & Disease Activity in NDMM Non-transplant Eligible
Details : Etentamig is a Antibody drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Multiple Myeloma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
July 31, 2025
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Cyclophosphamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Lymphoma, B-Cell.
Lead Product(s): Cyclophosphamide,Doxorubicin Hydrochloride,Epcoritamab,Etoposide,18-F Fludeoxyglucose,Prednisone,Rituximab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Cytotoxic Drug
Recipient: University of Washington
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 31, 2025
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Cyclophosphamide,Doxorubicin Hydrochloride,Epcoritamab,Etoposide,18-F Fludeoxyglucose,Prednisone,Rituximab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : University of Washington
Deal Size : Inapplicable
Deal Type : Inapplicable
Epcoritamab + Dose-Adjusted EPOCH-R Safety & Efficacy In Aggressive B-Cell NHL
Details : Cyclophosphamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Lymphoma, B-Cell.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
July 31, 2025
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Risankizumab is a Antibody drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Colitis, Ulcerative.
Lead Product(s): Risankizumab,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 17, 2025
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Risankizumab,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Risankizumab in Young Participants with Ulcerative Colitis
Details : Risankizumab is a Antibody drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Colitis, Ulcerative.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
July 17, 2025
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
ABBV-932 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.
Lead Product(s): ABBV-932,Itraconazole
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 17, 2025
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ABBV-932,Itraconazole
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ABBV-932 + Itraconazole Safety and PK In Healthy Adults
Details : ABBV-932 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 17, 2025
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Mirvetuximab Soravtansine is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Ovarian Neoplasms.
Lead Product(s): Mirvetuximab Soravtansine,Bevacizumab,Carboplatin
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody-drug Conjugate
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 11, 2025
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mirvetuximab Soravtansine,Bevacizumab,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
IV Mirvetuximab Soravtansine Safety & Disease Activity In Adult Ovarian Cancer Patients
Details : Mirvetuximab Soravtansine is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Ovarian Neoplasms.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
July 11, 2025
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Allowed
Registration Country : Switzerland
Dosage Form : Powder For Solution For ...
Brand Name : Botox Allergan units
Dosage Strength :
Packaging :
Approval Date : 04/11/1994
Application Number : 52433
Regulatory Info : Allowed
Registration Country : Switzerland
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Allowed
Registration Country : Switzerland
Dosage Form : Powder For Solution For ...
Brand Name : Botox Allergan units
Dosage Strength :
Packaging :
Approval Date : 04/11/1994
Application Number : 52433
Regulatory Info : Allowed
Registration Country : Switzerland
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Allowed
Registration Country : Switzerland
Dosage Form : Powder For Solution For ...
Brand Name : Botox Allergan units
Dosage Strength :
Packaging :
Approval Date : 04/11/1994
Application Number : 52433
Regulatory Info : Allowed
Registration Country : Switzerland
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Allowed
Registration Country : Switzerland
Dosage Form : Powder For Solution For ...
Brand Name : Vistabel
Dosage Strength :
Packaging :
Approval Date : 15/10/2002
Application Number : 55955
Regulatory Info : Allowed
Registration Country : Switzerland
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Dosage Form : Solution For Injection
Brand Name : Skyrizi
Dosage Strength : 150mg
Packaging :
Approval Date : 21/05/2021
Application Number : 20200728000052
Regulatory Info : Approved
Registration Country : Sweden
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Dosage Form : Solution For Injection
Brand Name : Skyrizi
Dosage Strength : 150mg
Packaging :
Approval Date : 21/05/2021
Application Number : 20200728000045
Regulatory Info : Approved
Registration Country : Sweden
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Dosage Form : Solution For Injection
Brand Name : Skyrizi
Dosage Strength : 180mg
Packaging :
Approval Date : 24/07/2024
Application Number : 20230828000034
Regulatory Info : Approved
Registration Country : Sweden
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Dosage Form : Solution For Injection
Brand Name : Skyrizi
Dosage Strength : 360mg
Packaging :
Approval Date : 21/11/2022
Application Number : 20211129000077
Regulatory Info : Approved
Registration Country : Sweden
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Dosage Form : Concentrate For Solution...
Brand Name : Skyrizi
Dosage Strength : 600mg
Packaging :
Approval Date : 21/11/2022
Application Number : 20211129000084
Regulatory Info : Approved
Registration Country : Sweden
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Dosage Form : Solution For Injection
Brand Name : Skyrizi
Dosage Strength : 75mg
Packaging :
Approval Date : 26/04/2019
Application Number : 20180430000079
Regulatory Info : Approved
Registration Country : Sweden
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
ACETAMINOPHEN; HYDROCODONE BITARTRATE
Dosage Form : TABLET; ORAL
Proprietary Name : VICODIN HP
Dosage Strength : 660MG;10MG
Approval Date : 1996-09-23
Application Number : 40117
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
ACETAMINOPHEN; HYDROCODONE BITARTRATE
Dosage Form : TABLET; ORAL
Proprietary Name : VICODIN
Dosage Strength : 500MG;5MG
Approval Date : 1983-01-07
Application Number : 88058
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
ACETAMINOPHEN; HYDROCODONE BITARTRATE
Dosage Form : TABLET; ORAL
Proprietary Name : VICODIN ES
Dosage Strength : 750MG;7.5MG
Approval Date : 1988-12-09
Application Number : 89736
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
Dosage Form : INJECTABLE; INJECTION
Proprietary Name : ACYCLOVIR
Dosage Strength : EQ 50MG BASE/ML
Approval Date : 1999-07-26
Application Number : 75114
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD :
TE Code :
Dosage Form : SYRINGE
Proprietary Name : HUMIRA
Dosage Strength : 40MG/0.8ML
Approval Date :
Application Number : 125057
RX/OTC/DISCN :
RLD :
TE Code :
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD :
TE Code :
Dosage Form : VIAL
Proprietary Name : HUMIRA
Dosage Strength : 40MG/0.8ML
Approval Date :
Application Number : 125057
RX/OTC/DISCN :
RLD :
TE Code :
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code :
Dosage Form : SOLUTION/DROPS; OPHTHALMIC
Proprietary Name : LASTACAFT
Dosage Strength : 0.25%
Approval Date : 2010-07-28
Application Number : 22134
RX/OTC/DISCN : OTC
RLD : Yes
TE Code :
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code : AB
Dosage Form : TABLET; SUBLINGUAL
Proprietary Name : SAPHRIS
Dosage Strength : EQ 5MG BASE
Approval Date : 2009-08-13
Application Number : 22117
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code : AB
Dosage Form : TABLET; SUBLINGUAL
Proprietary Name : SAPHRIS
Dosage Strength : EQ 10MG BASE
Approval Date : 2009-08-13
Application Number : 22117
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code : AB
Dosage Form : TABLET; SUBLINGUAL
Proprietary Name : SAPHRIS
Dosage Strength : EQ 2.5MG BASE
Approval Date : 2015-03-12
Application Number : 22117
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB
Services
API Manufacturing
Pharma Service : API Manufacturing
Category : Contract Manufacturing
Sub Category : Overview
Pharma Service : API Manufacturing
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drug Product Manufacturing
API & Drug Product Development
Packaging
REF. STANDARDS & IMPURITIES
Inspections and registrations
ABOUT THIS PAGE



